MIL OSI Translation. Region: Germany / Germany –
Source: The Left”In the fight against antibiotic resistance is the constant development of new drugs and more affordable drugs are urgently required. The Federal government must use quickly for significantly greater investment in medical research and development in this area,“ explains Sylvia fork man, drug policy spokesperson of the group has LEFT and a member of the sub-Committee for global health, on the occasion of recent research by the NDR, in accordance with which, in spite of the increasing spread of resistant germs, a number of pharmaceutical companies from the research and development of new antibiotics withdrawn. Fork man continued:”The increase of resistant germs is considered as one of the biggest global threats, the WHO warns against ‘post-antibiotic era’. Since antibiotics should only be limited for a few days used, for pharmaceutical companies much lower profit prospects than with other drugs, for example against cancer or chronic diseases. However, the medical need may not coincide with the criteria of the market to the victims. Even now, every year, around 33,000 people in the EU, and hundreds of thousands die worldwide from the consequences of infections with resistant germs.We are calling on the Federal government, which is striving for a leadership role in the area of global health, to act now, to promote the research decided to make it more transparent and to ensure that research and development costs to be decoupled from price and sales volume of the product.“
EDITOR’S NOTE: This article is a translation. Apologies should the grammar and/or sentence structure need be perfect.